No Data
No Data
The Market Doesn't Like What It Sees From Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Yet
Shanghai Junshi Biosciences' Supplementary NDA Accepted by Chinese Regulator
Junshi Biosciences Announces the Acceptance of the Supplemental New Drug Application for Toripalimab Combined With Bevacizumab for the First-Line Treatment of Advanced Hepatocellular Carcinoma
HKEX News | Junshi Biosciences (01877) rose more than 4% as the new application for Trelagliptin monoclonal antibody was accepted.
Junshi Bio (01877) rose more than 4%. As of press time, it rose 4.11% to HKD 13.16 with a turnover of HKD 4.2279 million.
Express News | Shanghai Junshi Biosciences - Received Acceptance Notice From National Medical Products Administration
Express News | Shanghai Junshi Biosciences - Acceptance of Supplemental New Drug Application for Toripalimab in Combination With Bevacizumab
No Data